Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

Rybski, J A; Spier, C M; Miller, T P; Lippman, S M; McGee, D L; Grogan, T M

Rybski, J A; Spier, C M; Miller, T P; Lippman, S M; McGee, D L; Grogan, T M.

Afiliación

Rybski JA; a Departments of Pathology and Internal Medicine and the Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Spier CM; a Departments of Pathology and Internal Medicine and the Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Miller TP; a Departments of Pathology and Internal Medicine and the Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Lippman SM; a Departments of Pathology and Internal Medicine and the Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
McGee DL; a Departments of Pathology and Internal Medicine and the Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.
Grogan TM; a Departments of Pathology and Internal Medicine and the Arizona Cancer Center, University of Arizona, Tucson, Arizona, USA.

Leuk Lymphoma ; 6(1): 31-8, 1991.

Article en En | MEDLINE | ID: mdl-27457573

Palabras clave

Immunochemistry; lymphoma; major histocompatibility complex; prognosis; therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 1991 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google